Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydro-acarbose is a synthetic derivative of acarbose, belonging to the class of aminocyclitol glycosides and aminosaccharides. It is structurally similar to acarbose, an alpha-glucosidase inhibitor used in the management of type 2 diabetes. Dihydro-acarbose shares the core mechanism of action with acarbose by inhibiting enzymes responsible for carbohydrate digestion in the intestine, thereby reducing postprandial blood glucose spikes. The compound has a molecular formula C25H45NO18 and a molecular weight of approximately 647.6 g/mol[3][6]. While detailed clinical data on dihydro-acarbose itself are limited, its parent compound (acarbose) is well established as an oral antidiabetic agent that acts locally in the gut to delay carbohydrate absorption[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydro-acarbose.